# US 2015/0174206 A1 · Uses of interferons with altered spatial structure

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0174206 A1
- Document ID: US20150174206A1
- Status: Published application
- Kind: A1
- Application number: 14/607,083
- Filed: 2015-01-28
- Published: 2015-06-25
- Earliest claimed: 2003-08-28
- Assignees: Superlab Far East Limited
- Applicants: Superlab Far East Limited
- Inventors: Guangwen Wei
- Web page: https://patentgrep.com/patent/US20150174206A1

## CPC

- A61K 38/21: Interferons {[IFN]}
- A61K 38/212: {IFN-alpha}
- A61K 38/215: {IFN-beta}
- A61K 38/217: {IFN-gamma}
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 31/20: for DNA viruses
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

This invention provides a method for preventing or treating Severe Acute Respiratory Syndrome in a subject comprising administering to the subject an effective amount of recombinant super-compound interferon or a functional equivalent thereof. This invention provides a method for inhibiting the causative agent of Severe Acute Respiratory Syndrome comprising contacting the agent with an effective amount of super-compound interferon or its equivalent.

## Claims

### Claim at position 1

1-29. (canceled)

### Claim 30

A method for treating prostate tumor in a subject comprising administering to the subject an effective amount of a recombinant interferon having an amino acid sequence of SEQ ID NO:2, wherein the recombinant interferon is produced by a method comprising the steps of:
i) introducing into an E. coli host cell a polynucleotide comprising SEQ ID NO:1 that encodes the recombinant interferon, wherein the polynucleotide is cloned into an expression vector that allows expression of the recombinant interferon in the E. Coli host cell;
ii) culturing the host cell in an appropriate condition for the expression of the recombinant interferon; and
iii) harvesting the expressed recombinant interferon.

### Claim 31 (depends on 30)

The method of claim 30, wherein the effective amount of the recombinant interferon is from nanogram to microgram.

### Claim 32 (depends on 30)

The method of claim 30, wherein the interferon is administered orally, via vein injection, muscle injection, peritoneal injection, subcutaneous injection, nasal or mucosal administration, or by inhalation.

### Claim 33 (depends on 30)

The method of claim 30, wherein the interferon is administered subcutaneously or intramuscularly at a dose of higher than or equal to 10 million or 20 million International Units per square meter of surface area.

### Claim 34 (depends on 30)

The method of claim 30, wherein the interferon is a lyophilized interferon prior to its dissolution for administration.

### Claim 35 (depends on 30)

The method of claim 30, wherein the interferon is administered following the protocol of 9 μg, 15 μg or 24 μg injections per day, 3 times a week, for a total of 24 weeks.

### Claim 36

A method for treating prostate tumor in a subject comprising administering to the subject an effective amount of a recombinant interferon having an amino acid sequence of SEQ ID NO:2, wherein the recombinant interferon is produced by a method comprising the steps of:
i) introducing into a host cell a polynucleotide comprising SEQ ID NO:1 that encodes the recombinant interferon;
ii) culturing the host cell in an appropriate condition for the expression of the recombinant interferon; and
iii) harvesting the expressed recombinant interferon.

### Claim 37 (depends on 36)

The method of claim 36, wherein the polynucleotide is cloned into an expression vector that allows expression of the recombinant interferon in the host cell.

### Claim 38 (depends on 36)

The method of claim 36, wherein the effective amount of the recombinant interferon is from nanogram to microgram.

### Claim 39 (depends on 36)

The method of claim 36, wherein the interferon is administered orally, via vein injection, muscle injection, peritoneal injection, subcutaneous injection, nasal or mucosal administration, or by inhalation.

### Claim 40 (depends on 36)

The method of claim 36, wherein the interferon is administered subcutaneously or intramuscularly at a dose of higher than or equal to 10 million or 20 million International Units per square meter of surface area.

### Claim 41 (depends on 36)

The method of claim 36, wherein the interferon is a lyophilized interferon prior to its dissolution for administration.

### Claim 42 (depends on 36)

The method of claim 36, wherein the interferon is administered following the protocol of 9 μg, 15 μg or 24 μg injections per day, 3 times a week, for a total of 24 weeks.

### Claim 43

A method for treating prostate tumor in a subject comprising administering to the subject an effective amount of a recombinant interferon, wherein the interferon has the amino acid sequence of SEQ ID NO:2 and is encoded by the nucleotide sequence SEQ ID NO:1.

### Claim 44 (depends on 43)

The method of claim 43, wherein the effective amount of the recombinant interferon is from nanogram to microgram.

### Claim 45 (depends on 43)

The method of claim 43, wherein the interferon is administered orally, via vein injection, muscle injection, peritoneal injection, subcutaneous injection, nasal or mucosal administration, or by inhalation.

### Claim 46 (depends on 43)

The method of claim 43, wherein the interferon is administered subcutaneously or intramuscularly at a dose of higher than or equal to 10 million or 20 million International Units per square meter of surface area.

### Claim 47 (depends on 43)

The method of claim 43, wherein the interferon is a lyophilized interferon prior to its dissolution for administration.

### Claim 48 (depends on 43)

The method of claim 43, wherein the interferon is administered following the protocol of 9 μg, 15 μg or 24 μg injections per day, 3 times a week, for a total of 24 weeks.
